Fenazid

General characteristics. Structure:

Active вещество:изоникотиноилгидразин sulfate gland a dihydrate (Феназид®) — 250 mg.

Excipients: potato starch — 57 mg, stearate calcium monohydrate — 3 mg.

Pharmacological properties:

Pharmacodynamics. Феназид® — antitubercular drug. It is active concerning tuberculosis mycobacteria. Modification of a molecule of an isoniazid by a complex formation with iron is the cornerstone of pharmacological action of Fenazida®. It provides tuberculosis chemotherapy as the chelate node of a molecule of hydrazide of isonicotinic acid (GINK) blocked by iron loses ability to interaction with active centers of metallic enzymes, and inclusion of primary amino group of a hydrazine in a chelate cycle of a complex interferes with interaction with N-acetyltransferase. In this regard Fenazid® is low-toxic drug at which use correction of single and course doses of drug depending on the speed of its acetylation is not required.

 

Pharmacokinetics. Феназид® it is slowly soaked up, time of achievement of the maximum concentration of drug in blood of 5-6 hours, an elimination half-life makes 7,2 hour.

Indications to use:

Феназид® it is shown at complex therapy of TB patients of various localization, including at associated diseases of the central nervous system, liver and bad portability of drugs of hydrazide of isonicotinic acid (GINK).

Route of administration and doses:

Inside, in 30–40 min. after food. In the first day accept 250 mg (1 tab.) in the morning (for specification of individual portability), further, in the absence of side reactions, on 250 mg in the morning and in the evening, within 6 months.

Features of use:

In the course of treatment of Fenazidom® control of the electrocardiogram and a koagulogramma is necessary systematic (at least 1 time a month).

Side effects:

Perhaps cardiotoxic action, acceleration of processes of a thrombogenesis, myocarditis, headache, dispeptic frustration, hypofunction of a thyroid gland, hemosiderosis of parenchymatous bodies.

Interaction with other medicines:

As Fenazid® is derivative GINK (chelate компдекс an isoniazid and bivalent iron), combined use of Fenazida® and isoniazid contraindicated.

Contraindications:

Hypersensitivity, pulmonary heart, coronary heart disease (CHD), disturbance of coagulability of blood, dysfunction of a thyroid gland, pregnancy, feeding by a breast, children's age.

Overdose:

Symptoms: strengthening of expressiveness of side reactions. Treatment: drug withdrawal, gastric lavage, symptomatic therapy. The specific antidote is not established.

Storage conditions:

In the dry place protected from light at a temperature not above 25 °C. 

To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets of 250 mg. On 50 pieces in a polymeric can or on 10 tablets in a blister strip packaging. Each can or 5 blister strip packagings together with the application instruction are placed in a pack from a cardboard.